At a glance
- Originator GlaxoSmithKline
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Alpha 2 adrenergic receptor antagonists; Dopamine D1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 08 Dec 1998 Preclinical development for Parkinson's disease in Netherlands (unspecified route)